Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?

Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?

Bibliographic Details
Main Author:	Jong Eun Yeon
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2018-09-01
Series:	Clinical and Molecular Hepatology
Subjects:	Chronic hepatitis C Genotype 2 Sofosbuvir Ribavirin
Online Access:	http://e-cmh.org/upload/pdf/cmh-2018-1009.pdf

Similar Items

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
by: Young Min Kim, et al.
Published: (2018-09-01)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
by: Tatsuo Kanda, et al.
Published: (2017-05-01)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01)

Real-life results of sofosbuvir based therapy for patients with hepatitis C
by: D. G. Zhivitsa, et al.
Published: (2019-09-01)

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
by: Chen-Hua Liu, et al.
Published: (2021-10-01)

Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China
by: Abulitifu Y, et al.
Published: (2022-11-01)

Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients
by: Muhammad Ikhlaq, et al.
Published: (2018-12-01)

Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study
by: B Kirushnan, et al.
Published: (2016-01-01)

Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
by: Chantelli Iamblaudiot Razafindrazoto, et al.
Published: (2021-06-01)

Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis
by: Tingting Tao, et al.
Published: (2017-02-01)

Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study
by: Zubia Jamil, et al.
Published: (2018-05-01)

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
by: Hee Yeon Seo, et al.
Published: (2020-05-01)

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
by: Steven Flamm, et al.
Published: (2023-09-01)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
by: L.P. Zanaga, et al.

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience
by: Tang Q, et al.
Published: (2021-06-01)

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
by: Ahmed OA, et al.
Published: (2018-03-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes
by: Rana A. Ali, et al.
Published: (2024-03-01)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
by: Mir F, et al.
Published: (2017-02-01)

Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
by: Woo Jin Chung
Published: (2012-09-01)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
by: Mohammed A Babatin, et al.
Published: (2019-01-01)

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study
by: Stefan Bourgeois, et al.
Published: (2020-01-01)

EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS
by: Sumetha Yaseen, et al.
Published: (2020-04-01)

Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial
by: Shafiq Ur Rehman Cheema, et al.
Published: (2019-11-01)

Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan
by: Hung-Chih Chiu, et al.
Published: (2021-03-01)

Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients
by: Engy A. Wahsh, et al.
Published: (2018-03-01)

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
by: Sung Yong Han, et al.
Published: (2021-05-01)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
by: Noha Anwar Hassuna, et al.
Published: (2022-12-01)

Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
by: Chen-Hua Liu, et al.
Published: (2020-12-01)

Evaluation of combination therapy with Interferon and Ribavirin in patients with chronic hepatitis C : a genotype based study
by: Y. Bafandeh, et al.
Published: (2007-01-01)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
by: Soon Kyu Lee, et al.
Published: (2022-11-01)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C
by: Jyh-Jou Chen, et al.
Published: (2022-11-01)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
by: Young Kul Jung, et al.
Published: (2013-03-01)

Treatment Efficacy of Sofosbuvir and Ribavirin Combination at Two Weeks in Chronic Hepatitis C
by: Aqsa Naseer
Published: (2017-12-01)

Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Edmundo P.A. Lopes, et al.

Therapy with interferon-a plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Lopes Edmundo P.A., et al.
Published: (2003-01-01)

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection
by: Hussien Ahmed, et al.
Published: (2017-03-01)

DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?
by: Marcela Pezzoto LAURITO, et al.

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
by: Pol S, et al.
Published: (2016-03-01)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020-09-01)